IBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
IBIO, INC. (IBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 157.77% for the 9-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2024-05-13
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-09-30 was 157.77%.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2017-09-30 was 103.10%.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-09-30 was 112.17%, a 16.00% increase year-over-year.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-09-30 was 96.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month |
|---|---|---|---|
| 2024-03-31 | 157.77% 10-Q · filed 2024-05-13 | ||
| 2023-12-31 | 157.77% 10-Q · filed 2024-02-09 | ||
| 2023-09-30 | 157.77% 10-Q · filed 2023-11-14 | ||
| 2021-03-31 | 97.50% 10-Q · filed 2021-05-17 | ||
| 2020-12-31 | 97.50% 10-Q · filed 2021-02-16 | ||
| 2020-03-31 | 97.50% 10-Q · filed 2020-05-15 | ||
| 2018-03-31 | 103.10% 10-Q · filed 2018-05-11 | ||
| 2017-12-31 | 103.10% 10-Q · filed 2018-02-14 | ||
| 2017-09-30 | 103.10% 10-Q · filed 2017-11-09 | ||
| 2017-03-31 | 104.38% 10-Q · filed 2017-05-15 | ||
| 2015-12-31 | 112.17% 10-Q · filed 2016-02-22 | ||
| 2015-09-30 | 112.17% 10-Q · filed 2015-11-13 | ||
| 2014-09-30 | 96.70% 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |